The efficacy of eszopiclone 3 mg compared to placebo in the treatment of insomnia secondary to perimenopause or menopause.

Trial Profile

The efficacy of eszopiclone 3 mg compared to placebo in the treatment of insomnia secondary to perimenopause or menopause.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2012

At a glance

  • Drugs Eszopiclone (Primary)
  • Indications Insomnia; Menopause
  • Focus Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2008 Actual number of patients (410) added as reported by ClinicalTrials.gov.
    • 09 Jun 2008 Primary endpoint of mean sleep latency added as reported by ClinicalTrials.gov.
    • 09 Jun 2008 Actual start date (Feb 2004) and end date (Jan 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top